Skip to main content
OpenTrials
Completed

NCT Number: NCT04812379

Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)

To investigate the safety for an observation period of 52 weeks with use of Abilify prolonged release aqueous suspension for intramuscular (IM) injection in patients with bipolar I disorder for prevention of recurrence/relapse of mood episodes in the routine clinical setting. The early stage safety after the switching from oral aripiprazole to this IM injection is investigated including extrapyramidal syndrome and malignant syndrome. Information regarding efficacy is collected as well.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sex eligibility

All sexes

Study type

Observational

Primary location

Pharmacovigilance Department

Osaka, 540-0021, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-

Exclusion criteria

  • patients with a known hypersensitivity to aripiprazole

Treatment and study plan

Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)

Drug

The usual dose in adults is 400 mg of aripiprazole administered intramuscularly in the gluteal or deltoid muscle as a single dose once every 4 weeks. The dose may be decreased to 300 mg based on the patient's symptoms and tolerability.

Primary outcomes

  1. Safety Information (Adverse Event)

    Time frame: 52 weeks from the start date of Abilify prolonged release aqueous suspension for IM injection therapy

    Any untoward medicinal occurrence in a patient or clinical study subject administered a Medicinal Product and which does not necessarily have a causal relationship with this treatment (ICH-E2A Guideline).

    An Adverse Event can therefore be any unfavorable and unintended sign (e.g. abnormal laboratory finding), symptom, or disease temporally associated with the use of a Medicinal Product (Abilify Prolonged Release Aqueous Suspension), whether or not it is considered causally related to the Medicinal Product.

  2. Number of Special Situations (e.g. Maternal (pregnancy and breastfeeding) exposure, paternal (via semen) exposure or Overdose/Incorrect dosage)

    Time frame: 52 weeks from the start date of Abilify prolonged release aqueous suspension for IM injection therapy

    Collecting any Situations related to the use of an Otsuka product which may or may not be associated with an adverse event:

    • Maternal (pregnancy and breastfeeding) or paternal (via semen) exposure;
    • Exposure during breastfeeding;
    • Overdose/Incorrect dosage, misuse, abuse (e.g. patient sharing products);
    • Medication errors (e.g. patient took wrong dose);
    • Lack of therapeutic efficacy (e.g. the product doesn't work);
    • Occupational exposure (e.g.: nurse administering the product is exposed);
    • Cases of suspected transmission of infectious agents;
    • Use of suspected or confirmed falsified product(s) or quality defect of the product(s);
    • Withdrawal reactions;
    • Accidental exposure (e.g.: child takes parent's product);
    • Drug-drug/drug-food interactions;
    • Unintentional use of product in a non-approved population (e.g.: pediatric or geriatric population);
    • Disease progression/exacerbation of existing disease

    (Safety Information)

  3. Number of off-Label Use

    Time frame: 52 weeks from the start date of Abilify prolonged release aqueous suspension for IM injection therapy

    Collecting any type of off-Label Use that refers to situations where a product is intentionally used for a medical purpose not in accordance with the authorized product information. Off-label use also includes the intentional use in non-authorized population categories not indicated in the label.

    (Safety Information)

  4. Incidence of Serious Adverse Event (e.g. resulting in death or life-threatening)

    Time frame: 52 weeks from the start date of Abilify prolonged release aqueous suspension for IM injection therapy

    Collecting the number of any adverse drug experience/event occurring at any dose which

    • results in death
    • is life-threatening
    • requires inpatient hospitalization or prolonged of existing hospitalization
    • results in persistent or significant disability or incapacity
    • is a congenital anomaly/birth defect
    • is medically significant.

    (Safety Information)

  5. Incidence of Non-serious Adverse Events (i.e. all Adverse Events that do not meet the definition of a serious Adverse Event)

    Time frame: 52 weeks from the start date of Abilify prolonged release aqueous suspension for IM injection therapy

    Collecting the number of non-serious Adverse Events

    (Safety Information)

Secondary outcomes

  1. Number of patients who recurrence/relapse of Mood Episodes

    Time frame: 52 weeks from the start date of Abilify prolonged release aqueous suspension for IM injection therapy

    Collecting the number of patients who recurrence/relapse of Mood Episodes (Efficacy Information)

Sponsors and collaborators

Lead sponsor

Otsuka Pharmaceutical Co., Ltd.

Industry

Registry information

Official study title

Abilify Prolonged Release Aqueous Suspension for Intramuscular Injection Specified Drug-use Results Survey (Prevention of Recurrence/relapse of Mood Episodes in Bipolar I Disorder)

Important dates

Study start
2021
Primary completion
2023
Study completion
2024
First posted
Mar 23, 2021
Registry last updated
Mar 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.